Atara Biotherapeutics (NASDAQ:ATRA) Receives Buy Rating from Canaccord Genuity Group

Atara Biotherapeutics (NASDAQ:ATRA)‘s stock had its “buy” rating restated by Canaccord Genuity Group in a report issued on Tuesday,Benzinga reports. They presently have a $17.00 price objective on the biotechnology company’s stock. Canaccord Genuity Group’s price target would indicate a potential upside of 175.97% from the stock’s current price.

Other equities analysts have also recently issued reports about the stock. TD Cowen raised shares of Atara Biotherapeutics to a “strong-buy” rating in a research note on Friday, November 29th. Rodman & Renshaw began coverage on shares of Atara Biotherapeutics in a report on Friday, December 20th. They issued a “buy” rating and a $25.00 target price on the stock. HC Wainwright reissued a “neutral” rating on shares of Atara Biotherapeutics in a report on Tuesday, January 28th. Finally, RODMAN&RENSHAW lowered Atara Biotherapeutics from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 21st. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, three have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Atara Biotherapeutics has an average rating of “Moderate Buy” and an average price target of $17.75.

Atara Biotherapeutics Stock Down 10.7 %

NASDAQ ATRA opened at $6.16 on Tuesday. The firm has a market cap of $35.48 million, a P/E ratio of -0.24 and a beta of 0.49. Atara Biotherapeutics has a 52-week low of $5.40 and a 52-week high of $20.81. The business’s 50-day moving average price is $9.74 and its 200 day moving average price is $9.74.

Atara Biotherapeutics (NASDAQ:ATRA) last posted its quarterly earnings data on Friday, March 7th. The biotechnology company reported ($1.19) earnings per share for the quarter, topping analysts’ consensus estimates of ($3.82) by $2.63. The company had revenue of $32.75 million for the quarter, compared to analyst estimates of $20.58 million. As a group, analysts anticipate that Atara Biotherapeutics will post -10.39 earnings per share for the current year.

Institutional Trading of Atara Biotherapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Geode Capital Management LLC increased its holdings in Atara Biotherapeutics by 9.5% in the third quarter. Geode Capital Management LLC now owns 46,720 shares of the biotechnology company’s stock valued at $380,000 after buying an additional 4,043 shares in the last quarter. State Street Corp grew its holdings in shares of Atara Biotherapeutics by 52.3% in the 3rd quarter. State Street Corp now owns 22,353 shares of the biotechnology company’s stock worth $182,000 after acquiring an additional 7,680 shares during the period. FMR LLC increased its stake in Atara Biotherapeutics by 41.7% in the 3rd quarter. FMR LLC now owns 25,061 shares of the biotechnology company’s stock valued at $204,000 after purchasing an additional 7,381 shares in the last quarter. Staley Capital Advisers Inc. raised its holdings in Atara Biotherapeutics by 25.0% during the fourth quarter. Staley Capital Advisers Inc. now owns 50,000 shares of the biotechnology company’s stock worth $666,000 after purchasing an additional 10,000 shares during the last quarter. Finally, Vestal Point Capital LP boosted its position in Atara Biotherapeutics by 11.3% during the third quarter. Vestal Point Capital LP now owns 124,677 shares of the biotechnology company’s stock worth $1,014,000 after purchasing an additional 12,677 shares in the last quarter. Institutional investors and hedge funds own 70.90% of the company’s stock.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.